Rhabdomyosarcoma cells
To recognize Sarcoma Awareness Month, we are highlighting our researchers who are advancing research discovery in this field. Dr. Amy LeBlanc, is studying sarcomas in pet dogs, who develop cancer naturally like humans, to gain a better understanding of these tumors and to investigate novel treatments for people. We also have a concentration of investigators studying pediatric sarcomas. Dr. Javed Khan is pursuing the application of genomic techniques in the investigation of pediatric cancers like rhabdomyosarcoma to identify biomarkers and novel therapeutic targets and to translate these findings to the clinic. Dr. Brigitte Widemann is developing new therapies for the treatment of pediatric cancers including sarcomas. Dr. Christine Heske's focus is on translational and clinical research in the area of pediatric sarcomas as it relates to the identification and evaluation of new therapeutic targets and overcoming mechanisms of resistance. Dr. Paul Meltzer is investigating the genetic and epigenetic basis of bone and soft tissue sarcomas in children and adults. Dr. Troy McEachron is studying how genomic changes in osteosarcoma prevent immune recognition of cancerous cells and how to improve the efficacy of immunotherapy for osteosarcoma. Dr. Frederic Barr’s research focuses on recurrent chromosomal alteration in sarcomas, with an emphasis on rhabdomyosarcoma, as a biomarker for diagnosis and treatment. Dr. Jing Huang is studying the role of p53, a cancer suppressor, in osteosarcoma and mesenchymal stromal/stem cells, which are thought to be cells that can develop into osteosarcoma. Drs. Robert Yarchoan, Giovanna Tosato, and Joseph Ziegelbauer are focusing on Kaposi sarcoma from studying pathways and mechanisms of action with the aim of identifying therapeutic targets and developing new treatments for this HIV-associated cancer.
Explore our website further to learn about other CCR researchers who are conducting sarcoma research.
CCR has several clinical trials on sarcoma currently open and enrolling. Learn more.